Jigesh Shah, DO
Surgery · Dallas, TXNPI 1255627527
Payments from drug & device makers
Across 11 payments — averaging $312.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Transmedics, Inc.$2K
- Sanofi-aventis U.S. LLC$250
- Johnson & Johnson$238
- Davol Inc.$139
- Sirtex Medical Inc$135
- Veloxis Pharmaceuticals, Inc.$130
- plus $73 from 1 others
What the payments were for
- Travel & lodging$2,47272%
- Food & beverage$96528%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Transmedics, Inc. | 2 | $2,472 |
| Sanofi-aventis U.S. LLC | 2 | $250 |
| Johnson & Johnson | 3 | $238 |
| Davol Inc. | 1 | $139 |
| Sirtex Medical Inc | 1 | $135 |
| Veloxis Pharmaceuticals, Inc. | 1 | $130 |
| Clozex Medical Inc | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGAN CARE SYSTEM$2,472
- THYMOGLOBULIN$250
- Enseal$144
- Echelon Flex$144
- Phasix Mesh$139
- SIR-Spheres Microspheres$135
- Envarsus$130
How this compares
$3,437 in reported general payments places this provider in the 50th percentile of 1,830 surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Valganciclovir Hcl | 85 | $15,668 |
| EliquisApixaban | 16 | $9,145 |
| Atovaquone | 19 | $7,993 |
| Entecavir | 36 | $4,079 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 29 | $2,154 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $1,341 |
| Humulin N KwikpenInsulin Nph Human Isophane | 14 | $1,137 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 139 | $981 |
| Fluconazole | 13 | $916 |
| Novolog FlexpenInsulin Aspart | 12 | $879 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $758 |
| Tamsulosin Hcl | 106 | $480 |
| Furosemide | 51 | $291 |
| Pantoprazole Sodium | 61 | $225 |
| Methocarbamol | 42 | $225 |
Paid to pharmacies, not to this prescriber.
Other surgery in Dallas
- Sachin KukrejaDallas$645K
- Malcolm MacconmaraDallas$635K
- Walton TaylorDallas$369K
- Steven LeedsDallas$217K
- Aaron HoffmanDallas$210K
- Lam leDallas$180K
- Benjamin LeviDallas$145K
- Funda MericHouston$20.6M
- Michael HarkinsTomball$2.7M
- Lloyd StegemannCorpus Christi$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.